Clinical trials: sponsored by AbbVie
Relapsed/Refractory Non-Hodgkin's Lymphoma
A Pharmacokinetic Study to Access How the Body Absorbs and Removes ABT-199 in Adults With Non-Hodgkin's Lymphoma
A pharmacokinetic study to access how the body absorbs and removes ABT-199 in adults with Non-Hodgkin's Lymphoma.
- Trial name
- NCT02095574
- Testing
- [14C]ABT-199 (GDC-0199)
- Sponsor
- AbbVie
Cardiothoracic Surgery, Vascular Surgery
A Safety and Efficacy Trial of Multiple Dosing Regimens of ABT-719 for the Prevention of Acute Kidney Injury in Subjects Undergoing High Risk Surgery
This study will evaluate the safety and efficacy of ABT-719 in patients undergoing high risk major surgery.
- Trial name
- NCT01897519
- Testing
- ABT-719
- Where
- 23 sites in United States, Denmark
- Volunteers
- 56 people
- Sponsor
- AbbVie
Hypogonadism, Testosterone Deficiency
An Efficacy and Safety Study of ABT-SLV176 for the Treatment of Hypogonadal Men
This is an open-study with a 26 week open label treatment period followed by an optional 26 week open label extension. The total treatment period will be 52 weeks.
- Trial name
- NCT02082197
- Testing
- ABT-SLV176
- Where
- 42 sites in United States
- Sponsor
- AbbVie
Non-Hodgkin's Lymphoma
A Study to Assess the Effect of Rifampin on the Metabolism of ABT-199
This is an open-label multicenter, study to assess the pharmacokinetic interaction of rifampin with ABT-199 in up to 12 subjects with relapsed or refractory non-Hodgkin's lymphoma.
- Trial name
- NCT01969682
- Testing
- ABT-199, Rifampin
- Where
- United States
- Sponsor
- AbbVie
Absolute Bioavailability
Bioavailability of ABT-450 and ABT-267 With Ritonavir
A study to investigate the fraction of ABT-267 and ABT-450 absorbed by the body when given in combination with each other and Ritonavir(r).
- Trial name
- NCT02052362
- Testing
- ABT-450/r/ABT-267
- Where
- United Kingdom
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- AbbVie
Relative Bioavailability
Bioavailability of ABT-333 Within the Gastrointestinal Tract in Healthy Subjects
This open label, Phase 1 study is to investigate the relative bioavailability of ABT-333 when delivered within different sites of the gastrointestinal tract in 12 healthy subjects.
- Trial name
- NCT02052349
- Testing
- ABT-333
- Where
- United Kingdom
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- AbbVie
Alzheimer's Disease
Safety, Tolerability, and Pharmacokinetics of ABT-354 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors
This study will investigate safety, tolerability and pharmacokinetics of ABT-354 in up to 20 male and female subjects, between 55 to 90 years of age with mild to moderate Alzheimer's disease on stable doses of…
- Trial name
- NCT01908010
- Testing
- ABT-354
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- AbbVie